Dow Jones
34.433,77 +581,24 (+1,72%) Nasdaq
11.395,36 +411,58 (+3,75%) Nikkei 225
27.968,99 -58,85 (-0,21%) EUR/USD
1,0422 +0,0087 (+0,84%) BTC-EUR
16.372,13 +462,12 (+2,90%) CMC Crypto 200
405,45 +4,76 (+1,19%)
Editas Medicine, Inc. (EDIT)
| Chiusura precedente | 9,93 |
| Aperto | 9,90 |
| Denaro | 10,36 x 800 |
| Lettera | 10,37 x 800 |
| Min-Max giorno | 9,64 - 10,44 |
| Intervallo di 52 settimane | 9,59 - 33,70 |
| Volume | |
| Media Volume | 1.571.817 |
| Capitalizzazione | 714,791M |
| Beta (5 anni mensile) | 1,96 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,73 |
| Prossima data utili | 22 feb 2023 - 27 feb 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 17,57 |
- GlobeNewswire
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients Achieved proof of concept and identified a responder population In view of the small population, the Company will pause enrollment in the BRILLIANCE trial and seek to identify a collaboration partner to continue development of EDIT-101 Company to host a webinar today at 8:00 a.m. ET CAMBRIDGE, Mass.,
- GlobeNewswire
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to provide a clinical update on the Phase 1/2 BRILLIANCE trial for EDIT-101 this month CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome edi
- GlobeNewswire
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of 2022. To access the conference call: U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.Participants s
